

1 **Comparison of healthcare resource use and cost between influenza and COVID-19 vaccine**  
2 **coadministration and influenza vaccination only**

3 **Darshan Mehta<sup>a</sup>, Tianyu Sun<sup>a</sup>, Jane Wang<sup>a</sup>, Aaron Situ<sup>a</sup>, Yoonyoung Park<sup>a</sup>**

4 <sup>a</sup> *Moderna, Inc., Cambridge, MA, USA*

5 *Address for correspondence*

6 *Darshan Mehta*

7 *Email: Darshan.Mehta@modernatx.com*

8 **Abstract:**

9 Objective: To compare healthcare recourse utilizations (HCRU) and all-cause medical costs  
10 among individuals 50 years or older who received both influenza and COVID-19 vaccines on the  
11 same day and those that received influenza vaccine only

12 Methods: We conducted a retrospective cohort study leveraging Optum's de-identified  
13 Clinformatics® DataMart from 8/31/2021 to 7/31/2023. Individuals 50 years or older  
14 continuously enrolled in health plans for one year prior and until 7/31/2023 were included in the  
15 study. Subjects were categorized into 2 cohorts based on their vaccination status between  
16 8/31/2022 and 1/31/2023: receiving influenza and COVID-19 vaccine on same day (co-admin  
17 cohort) and receiving influenza vaccine only (influenza cohort). The association between  
18 vaccination status and all-cause, influenza-related, COVID-related, pneumonia-related, and  
19 cardiorespiratory-related hospitalization, as well as outpatient or emergency room visits and all-  
20 cause medical costs was estimated by weighted generalized linear models, adjusting for  
21 confounding by stabilized inverse probability of treatment weighting.

22  
23 Results: 613,156 (mean age: 71) and 1,340,011 (mean age: 72) individuals were included in the  
24 co-admin and influenza cohort respectively. After weighting, the baseline characteristics were  
25 balanced between cohorts. The co-admin cohort was at statistically significant lower risk of all-  
26 cause (RR: 0.95, 95%CI: 0.93-0.96), COVID-19-related (RR: 0.59, 95%CI: 0.56-0.63),  
27 cardiorespiratory-related (RR: 0.94, 95%CI: 0.93-0.96) and pneumonia-related (RR: 0.86,  
28 95%CI: 0.83-0.90) hospitalization but not influenza-related hospitalizations (RR: 0.91, 95%CI:  
29 0.81, 1.04) compared to influenza cohort. Co-administration was associated with 3% lower all-  
30 cause medical cost (cost ratio: 0.974, 95% CI: 0.968, 0.979) during the follow-up period  
31 compared to receiving influenza vaccine only.

32 Conclusion: Receiving both COVID-19 and influenza vaccines on the same day in comparison to  
33 receipt of influenza vaccine only was associated with reduced risk of HCRU, especially COVID-  
34 19 related hospitalization and all-cause medical costs. Interventions that increase vaccine  
35 coverage, particularly for COVID-19 might have public health and economic benefits.

36 **Background:**

37 Acute respiratory diseases caused by SARS-CoV-2 and influenza viruses impose a significant  
38 health burden. Since the pandemic COVID-19 has resulted in 6.9 million hospitalizations and  
39 1.1 million deaths in the United States (US).<sup>1</sup> In 2023, CDC estimates there were 850,000  
40 hospitalizations and 70,000 deaths due to COVID-19, most of them among older individuals.  
41 In the same year CDC estimates influenza caused up to 790,000 hospitalizations and up to  
42 69,000 deaths.<sup>2</sup>

43 Vaccines exist to protect the population against both COVID-19 and influenza disease. For  
44 the 2023/2024 season, CDC currently recommends influenza and COVID-19 vaccination for  
45 everyone greater than 6 months of age.<sup>3,4</sup> CDC recommends co-administration of both  
46 influenza and COVID-19 vaccines at the same visit for eligible individuals if timing is  
47 aligned.<sup>5</sup> Despite the CDC recommendations and prevailing unmet needs, COVID-19 vaccine  
48 uptake in the US has declined over time.<sup>6</sup> In the 2023/24 season, 22.5% of adults and 32.3%  
49 individuals with health conditions associated with higher risk of adverse outcomes received  
50 the COVID-19 vaccination.<sup>1</sup> The influenza vaccine coverage estimated by the CDC is  
51 relatively higher in 50 to 64 age group at 51.5% and in 65 years and older at 73.8%.<sup>7</sup>  
52 Ensuring sufficient vaccine coverage for both COVID-19 and influenza is crucial to reduce  
53 the associated significant burden of respiratory illnesses.

54 The suboptimal vaccine coverage leaves many adults and especially high-risk individuals like  
55 older adults at increased risk of severe influenza and COVID-19. Given the annual circulation  
56 and continuous evolution of both influenza and SARS-CoV-2, there remains a need to  
57 improve simultaneous vaccination uptake, especially in the most vulnerable populations, such  
58 as the elderly. Co-administration of vaccines during the same visit could be one strategy to  
59 increase the vaccination coverage rate.<sup>8</sup> However, literature is still evolving about the medical  
60 and cost outcomes associated with co-administration of the two vaccines in older adults. In  
61 this study, we examined the downstream HCRU and medical cost following co-administration  
62 of COVID-19 and influenza vaccines on the same day, compared to receiving influenza  
63 vaccine only in a given season.

64 **Methods:**

65 *Study design and participants:*

66 We conducted the study using the Optum Clinformatics Data Mart (CDM). The dataset is  
67 comprised of closed medical and pharmacy claims including a large proportion of Medicare  
68 Advantage plans. Data from August 31, 2021, to July 31, 2023, was used for the analyses and  
69 data extraction was performed on March 29, 2024. Adults greater than 50 years or older on  
70 the index date and continuously enrolled in health plans (no gap allowed) one year prior to  
71 index date and up to July 31, 2023, were eligible for the study. Index vaccination status was  
72 assessed between August 31, 2022, and January 31, 2023 (identification period), covering  
73 majority of the 2022/2023 seasonal vaccination season in the US. We included individuals  
74 who received at least one influenza vaccine or an influenza and COVID vaccine on the same  
75 day during the identification period. Key exclusion criteria were individuals with missing age,  
76 sex, insurance type and region information. We excluded patients who received influenza or  
77 COVID-19 vaccine during August 1-30, 2022, to exclude potential prior season vaccination.  
78 Individuals who received more than one influenza vaccine or more than one COVID-19  
79 vaccine during August 31, 2022 –July 31, 2023, were excluded (**Figure 1**).


80 The population was categorized into 2 cohorts based on their vaccination status during the  
81 identification period: those receiving influenza and COVID-19 vaccine on same day (co-  
82 admin cohort), aligned with CDC definition of co-administration<sup>5</sup> and those receiving  
83 influenza vaccine only (influenza cohort). For the influenza cohort, individuals who received  
84 COVID-19 vaccine between index date and July 31, 2023, were excluded. Similarly, for co-  
85 admin cohort, individuals who received influenza and COVID-19 vaccine on separate days  
86 were excluded. As the unvaccinated cohort would be considered different in terms of  
87 unobserved characteristics than people who got either COVID-19 or flu vaccine, to avoid the  
88 risk of unmeasured confounding we did not consider them as our referent.<sup>9</sup> Further, among  
89 individuals who got either COVID-19 or flu vaccine we considered the flu only cohort as our  
90 control as flu vaccination coverage rate is higher than COVID-19 vaccine coverage rate.

91 Study subjects were indexed by their date of vaccination for influenza and COVID-19 (co-  
92 admin cohort), or their date of vaccination for influenza (influenza cohort). Baseline period  
93 for covariate assessment was defined as 365 days prior to the index date, and follow-up  
94 period was defined as from 14 days post-index date to 194 days after the index date (i.e., 6

95 month of follow-up), up to July 31, 2023.

96

97 **Figure 1: Description of study design**



98

99 *Exposure and Outcomes*

100 Vaccination status as the exposure was determined using Current Procedural Terminology  
101 (CPT), Healthcare Common Procedure Coding System (HCPCS), and National Drug Codes  
102 (NDC) from any care setting (Supplementary Table 1). The healthcare resource utilization  
103 (HCRU) outcomes were defined as having one or more all-cause, influenza related, COVID-19  
104 related, pneumonia-related and cardiorespiratory-related hospitalizations during the follow-up,  
105 the number of outpatient or emergency room (OP/ER) encounters during the follow-up, and all-  
106 cause medical incurred during the follow-up. All-cause HCRU was defined as hospitalizations or  
107 OP/ER encounters due to any cause. Influenza, COVID-19, pneumonia-related and  
108 cardiorespiratory related HCRU was defined as hospitalization and OP/ER encounters with  
109 prespecified ICD-10 diagnosis codes (Supplementary Table 2) in any position associated with  
110 the claim. All-cause medical cost was defined as the medical cost associated with hospitalization  
111 or OP /ER counters due to any cause. The mean cost per patient was determined over the follow-  
112 up period. Costs were reported in 2023 USD.

113

114 *Covariates*

115 Demographic characteristics such as, age, gender, region, insurance type and race/ethnicity

116 were assessed on index date. Baseline comorbidities were identified during the baseline  
117 period using ICD-10-CM diagnosis or procedure, HCPCS, and CPT-4 codes, and included as  
118 binary variables. Utilizations of other vaccinations or cancer screening during the baseline  
119 period was described. Immunocompromised status was derived based on previously  
120 established algorithm.<sup>10,11</sup> The list of full variables with descriptive statistics is provided in  
121 supplemental table 3.

## 122 *Statistical methods*

123 Categorical baseline characteristics were reported as frequency (n) and percentage. Continuous  
124 variables were reported as mean with standard deviation (SD) and median with interquartile.  
125 Absolute standardized differences (ASDs) were calculated to compare the distribution of  
126 baseline demographic and characteristics between the two cohorts. Hospitalization outcome was  
127 analyzed by the proportion of individuals with one or more hospitalization. OP/ER outcomes  
128 were analyzed by the mean number of outcomes.

129 We used the stabilized inverse probability of treatment weighting (IPTW) to adjust for potential  
130 confounding. Baseline demographic, clinical characteristics that were identified as potential  
131 confounders and had ASD >0.1 were included in the IPTW calculation. The list of selected  
132 baseline variables and their descriptive statistics are shown in Table 2. ASDs were calculated  
133 after weighting again to determine whether there is residual imbalance among the measured  
134 variables.

135 Generalized linear models (GLM) were applied to estimate the association between vaccination  
136 status and HCRU or cost outcomes during follow-up. For count-type OP/ER outcomes, Poisson  
137 distribution with log link function was used to estimate the rate ratio. Pearson Chi-square scale  
138 was used to adjust for overdispersion of count data. For right-skewed cost outcome, gamma  
139 distribution with log-link was used to estimate the cost ratio. A negligible cost was added (0.1  
140 cent) to patients with zero cost. For binary-type hospitalization outcome, robust Poisson  
141 regression was applied to estimate the relative risk.<sup>12</sup> All statistical analyses were performed with  
142 2-sided alpha at 0.05 level. Data extraction and cleaning were conducted using the Aetion  
143 Evidence Platform. Statistical analyses were conducted using SAS® version 9.4 (SAS Institute  
144 Inc., NC, USA).

145

146 *Ethics review*

147 The study dataset only contains de-identified data as per the de-identification standard defined  
 148 in Section §164.514(a) of the Health Insurance Portability and Accountability Act of 1996  
 149 (HIPAA) Privacy Rule. The process by which the data is de-identified is attested to through a  
 150 formal determination by a qualified expert as defined in Section §164.514(b)(1) of the  
 151 HIPAA Privacy Rule. Therefore, the study was considered exempt from Institutional Review  
 152 Board approval and for obtaining informed consent.

153 **Results**

154 *Baseline demographics and clinical characteristics*

155 Table 1 provides the sample attrition table. Total 1,953,167 individuals met the study  
 156 inclusion and exclusion criteria. Based on their vaccination status, 613,156 and 1,340,011  
 157 individuals were included in the co-admin and influenza cohort respectively.

158 **Table 1: Attrition table summarizing inclusion and exclusion criteria**

	<b>Co-admin cohort</b>	<b>Influenza cohort</b>
Patients were identified from Optum CDM during Aug 31, 2022- Jul31, 2023.	Who had received COVID-19 and influenza vaccine on the same day: 1,425,838	Who had received at least one influenza vaccine: 6,224,981
<b>Exclusion</b>		
1. Insufficient enrollment during baseline and till July 31, 2023	904,331	3,957,199
2. Missing demographics (age, sex, payer, state)	903,736	3,954,266
3. Age < 18 on index date	856,825	3,606,716
4. Any COVID-19 and/or Influenza Vaccine during Aug1-30, 2022	847,668	3,540,628
5. For co-admin cohort: more than one COVID and/or Influenza vaccine during Aug 31, 2022 – Jul 31, 2023*	777,928	1,655,246



For influenza cohort: any COVID-19 vaccine or more than one influenza vaccine during Aug 31, 2022 - Jul31, 2023		
6. Index vaccination after January 31, 2023	769,241	1,617,185
7. Patients under 50-year-old	613,156	1,340,011
<b>Final Cohort</b>	<b>613,156</b>	<b>1,340,011</b>

159 \*For the co-admin cohort, 1086 individuals were removed as they received more than 2 COVID-19  
 160 vaccines. 58,554 individuals were removed as they received 2 COVID-19 vaccines.

161 Table 2 summarizes the selected baseline demographic and clinical characteristics for the two  
 162 cohorts (Supplementary table 3 for the entire table). The mean age of the cohorts was 71 and  
 163 72 for co-admin and influenza cohort, respectively. Across both cohorts, most of the  
 164 individuals were 65+ and hence were predominantly insured by Medicare Advantage plans.  
 165 The overall comorbidity burden quantified by mean Charlson-Quan comorbidity index score  
 166 was under 1 in both cohorts, though a trend towards influenza cohort having higher  
 167 proportion of individuals with specific comorbidity was observed. In co-admin cohort during  
 168 the baseline period, higher proportion of individuals utilized preventive health services such  
 169 as other vaccines and screening procedures, while the level of healthcare utilization  
 170 (hospitalization, OP/ER encounters) was lower compared to influenza cohort. All baseline  
 171 variables were well balanced after weighting.

172 **Table 2: Baseline demographic and clinical characteristics**

	<b>Co-admin Cohort N = 613,156</b>	<b>Influenza Cohort N =1,340,011</b>	<b>ASD (Prior to Weighting)</b>	<b>ASD (Post- Weighting)</b>
<b>Age on Index Date</b>				
mean (SD)	71 (9.18)	72 (9.42)	0.097	0.009
median (IQR)	71.00 (66.00,77.00)	72.00 (67.00,79.00)		

<b>Gender, n(%)</b>				
Female	327,738 (53.45%)	775,100 (57.84%)	0.088	0.003
Male	285,418 (46.55%)	564,911 (42.16%)	0.088	0.003
<b>Race, n(%)</b>				
White	476,306 (77.68%)	948,828 (70.81%)	0.158	0.021
Asian	20,011 (3.26%)	45,918 (3.43%)	0.009	0.008
Black	44,449 (7.25%)	133,074 (9.93%)	0.096	0.005
Hispanic	39,092 (6.38%)	126,389 (9.43%)	0.113	0.02
Missing/unknown	33,298 (5.43%)	85,802 (6.40%)	0.041	0.003
<b>Insurance, n(%)</b>				
Commercial	125,618 (20.49%)	222,061 (16.57%)	0.101	0.014
Medicare Advantage	487,538 (79.51%)	1,117,950 (83.43%)	0.101	0.014
<b>Region, n(%)</b>				
Northeast	76,274 (12.44%)	169,717 (12.67%)	0.007	0.002
Midwest	169,838 (27.70%)	279,674 (20.87%)	0.16	0.001
South	197,075 (32.14%)	636,165 (47.47%)	0.317	0.001
West	169,969 (27.72%)	254,455 (18.99%)	0.207	0.002
<b>Charlson-Quan score</b>				
mean (SD)	0.40 (0.86)	0.51 (0.94)	0.121	0.004
median (IQR)	0.00 (0.00,1.00)	0.00 (0.00,1.00)		
<b>Comorbidities, n(%)</b>				
Anemia	87,415 (14.26%)	245,452 (18.32%)	0.11	0.003
Asthma	42,702 (6.96%)	101,029 (7.54%)	0.022	0.001
Chronic kidney disease	101,050 (16.48%)	271,729 (20.28%)	0.098	0.002
Hypertension	385,012 (62.79%)	945,512 (70.56%)	0.165	0.003
Obesity	121,794 (19.86%)	276,265 (20.62%)	0.019	0.003
Influenza infection	2,887 (0.47%)	10,386 (0.78%)	0.039	0.003
Smoking	107,972 (17.61%)	255,674 (19.08%)	0.038	0.003

COVID-19 Infection	54,125 (8.83%)	169,947 (12.68%)	0.125	0.004
Pneumonia	15,499 (2.53%)	53,782 (4.01%)	0.084	0.004
<b>Receipt of COVID-19 vaccine in prior year, n(%)</b>	366,183 (59.72%)	373,455 (27.87%)	0.678	0.007
<b>Receipt of influenza vaccine in prior year, n (%)</b>	259,654 (42.35%)	495,290 (36.96%)	0.11	0.012
<b>Other Vaccine Utilization, n(%)</b>	126,327 (20.60%)	222,027 (16.57%)	0.104	0.004
<b>Any Cancer screening procedure, n(%)</b>	235,000 (38.33%)	488,070 (36.42%)	0.039	0.006
<b>Immunocompromised status, n(%)</b>	80,046 (13.05%)	185,017 (13.81%)	0.022	0.002
<b>Hospitalizations during baseline, n(%)</b>	47,609 (7.76%)	139,409 (10.40%)	0.092	0.005
<b>Number of all-cause OP/ER encounter at baseline</b>				
mean (SD)	17.92 (18.75)	20.60 (23.46)	0.126	0.001
median (IQR)	12.00 (6.00,23.00)	14.00 (7.00,26.00)		
<b>Index Vaccination Year and Month, n(%)</b>				
2022 AUG-SEP	165,517 (26.99%)	277,656 (20.72%)	0.148	0.015
2022 OCT	286,133 (46.67%)	579,235 (43.23%)	0.069	0.008
2022 NOV	105,510 (17.21%)	303,245 (22.63%)	0.136	0.009
2022 DEC	43,530 (7.10%)	133,756 (9.98%)	0.103	0.016
2023 JAN	12,466 (2.03%)	46,119 (3.44%)	0.086	0.008

173 SD: standard deviation; IQR: interquartile range; ASD: absolute standardized difference; OP/ER: outpatient or  
 174 emergency room

175 *HCRU and cost outcomes*

176 The co-administration of influenza and COVID-19 vaccines on the same day was associated  
 177 with 5% lower risk of all-cause hospitalizations (RR: 0.95, 95%CI: 0.93-0.96), 41% lower  
 178 risk of COVID-19-related hospitalizations (RR: 0.59, 95%CI: 0.56-0.63), 6% lower risk of  
 179 cardiorespiratory-related hospitalizations (RR: 0.94, 95%CI: 0.93-0.96), and 14% lower risk  
 180 of pneumonia-related hospitalizations (RR: 0.86, 95%CI: 0.83-0.90), compared to receiving  
 181 influenza vaccine only. The association between vaccination status and influenza-related  
 182 hospitalizations was not statistically significant (RR: 0.91, 95%CI: 0.81, 1.04). Similar trends  
 183 were also observed for number of OP/ER encounters. (Table 3).

184 **Table 3: Association between vaccination status and HCRU**

outcomes	Co-admin Cohort	Influenza Cohort	Weighted RR (95% CI)**
<b>All-cause</b>			
Hospitalizations during follow-up, (95% CI)*	5.19% (5.13, 5.24)	6.65% (6.61, 6.69)	0.95 (0.93, 0.96)
Mean number of OP/ER encounter during follow-up, (95% CI)#	9.204 (9.177, 9.230)	10.800 (10.777, 10.823)	0.96 (0.95, 0.96)
<b>COVID-19-related</b>			
Hospitalizations during follow-up, (95% CI)*	0.27% (0.26, 0.28)	0.53% (0.52, 0.54)	0.59 (0.56, 0.63)
Mean number of OP/ER encounter during follow-up, (95% CI)#	0.067 (0.065, 0.069)	0.110 (0.109, 0.112)	0.68 (0.66, 0.70)
<b>Cardiorespiratory-related</b>			
Hospitalizations during follow-up, (95% CI)*	4.62% (4.57, 4.68)	6.07% (6.03, 6.11)	0.94 (0.93, 0.96)
Mean number of OP/ER encounter during follow-up, (95% CI)#	3.125 (3.110, 3.140)	4.125 (4.113, 4.138)	0.94 (0.93, 0.94)
<b>Pneumonia-related</b>			
Hospitalizations during follow-up, (95% CI)*	0.71% (0.69, 0.73)	1.09% (1.07, 1.11)	0.86 (0.83, 0.90)

Mean number of OP/ER encounter during follow-up, (95% CI)#	0.059 (0.057, 0.061)	0.094 (0.092, 0.096)	0.87(0.84, 0.91)
<b>Influenza-related</b>			
Hospitalizations during follow-up, (95% CI)*	0.07% (0.07, 0.08)	0.10% (0.09, 0.10)	0.91 (0.81, 1.04)
Mean number of OP/ER encounter during follow-up, (95% CI)#	0.012 (0.012, 0.013)	0.017 (0.016, 0.017)	0.86 (0.81, 0.92)

185 \*\*influenza cohort as the reference

186 \* Relative risk is calculated by robust Poisson regression

187 # Relative risk is calculated by Poisson regression using Pearson's chi-square statistics to adjust for variance  
188 overdispersion.

189 HCRU: healthcare resource utilization; RR: relative risk; CI: confidence interval; OP/ER: outpatient or  
190 emergency room

191

192 All-cause medial costs during the follow-up period for two cohorts are summarized in Table  
193 4. On average, individuals in co-admin cohort had lower cost (\$7,868) than individuals in  
194 influenza cohort (\$9,415). After adjusting for baseline variables, co-admin cohort had 3% less  
195 all-cause medical cost (cost ratio = 0.974, 95% CI: 0.968, 0.979) during the follow-up period  
196 compared to influenza cohort.

197 **Table 4: Association between vaccination status and all-cause medical costs**

	<b>Co-admin</b>	<b>Influenza</b>	<b>Weighted cost ratio (95% CI)</b>
N*	612,689	1,339,079	
Mean (SD)	\$7,868 (\$21,492)	\$9,415 (\$25,025)	0.974 (0.968, 0.979)**
Median (IQR)	\$1,853 (\$596, \$5,730)	\$2,200 (\$726, \$6,844)	

198 \*Patients with negative cost during baseline or follow-up had been excluded.

199 \*\*IPTW was recalculated after exclusion. Generalized linear model with gamma distribution and log link  
200 function was used to estimate the cost ratio. Zero cost had been replaced with 1/10 cent.

201 SD: standard deviation; IQR: interquartile range

202

203 **Discussion:**

204 The study result indicates that receiving both influenza and COVID-19 vaccination on same  
205 day was associated with significantly reduced all-cause, COVID-19 related, pneumonia  
206 related, and cardiorespiratory related hospitalization risks and average number of OP/ER  
207 visits compared to receiving influenza vaccine only during the 2022/2023 season. The  
208 reduction in risk was more pronounced for COVID-19 related hospitalization. Driven by  
209 reduced hospitalization and OP/ER visits, all cause medical cost was significantly lower with  
210 vaccine co-administration on same day as compared to receiving influenza vaccine only. To  
211 our knowledge, this is among the first studies to compare medical costs associated with co-  
212 administration of COVID-19 and influenza vaccines.

213 We found that co-admin cohort had reduced risk of influenza-related OP/ER encounters than  
214 influenza cohort. Excluding the possibility of a chance finding, this observation can be a  
215 result of residual confounding given that influenza cohort in general had higher medical  
216 needs. McGrath et al. in a retrospective cohort study of US adults also concluded that among  
217 individuals 65 years or older, co-administration of BNT162b2 BA.4/5 bivalent mRNA  
218 COVID-19 vaccine and influenza vaccine was associated with lower incidence of influenza-  
219 related outcomes compared to receiving influenza vaccine alone. When they calibrated using  
220 negative control outcomes, the observed association moved closer to the null and was no  
221 longer statistically significant.<sup>13</sup>

222 Following favorable evidence from cohort study and clinical trials<sup>14-16</sup> on safety and  
223 immunogenicity, co-administration of influenza and COVID-19 vaccines on the same day  
224 have been recommended by most public authorities,<sup>17</sup> including the CDC.<sup>5</sup> The safety of co-  
225 administration strategy was further studied in a recent VAERS database analysis which  
226 concluded that co-administration of bivalent mRNA COVID-19 and seasonal influenza  
227 vaccines did not reveal any unusual or unexpected patterns of AEs.<sup>18</sup> CDC ACIP recently  
228 proposed changing the COVID-19 recommendation timelines from current Sept to June to  
229 align with the influenza recommendation timelines.<sup>19</sup> However, the uptake of co-  
230 administration strategy is still growing. Among a large sample of older U.S. Medicare  
231 beneficiaries who received an mRNA COVID-19 booster vaccine, the prevalence of vaccine  
232 co-administration with an influenza vaccine was 11.1% in 2021 and 36.5% in 2022, and  
233 varied widely across U.S. counties.<sup>20</sup>

234 Various aspects of the benefits with both influenza and COVID-19 vaccination have been  
235 described in prior literature. Recent cost effectiveness analyses by CDC concludes that  
236 influenza vaccination results in net health gains but also incurs net costs for all adult age  
237 cohorts, except for vaccination of high-risk adults >50 years which was projected to be cost  
238 saving.<sup>21</sup> Similarly, vaccination against COVID-19 has been shown to be cost effective and  
239 reduce burden to the health care system.<sup>22</sup> Ensuring sufficient vaccine coverage for both  
240 COVID-19 and influenza is a crucial driver to reduce the burden to health care system of  
241 significant respiratory illnesses. Improvement in vaccination coverage and likelihood of  
242 completing all recommended vaccinations through use of a multi-component, combination  
243 vaccine was previously demonstrated in pediatric space.<sup>23,24</sup> Several multi-component  
244 combination vaccines against influenza and COVID-19 are in clinical development,<sup>25-27</sup>  
245 which if approved could help in increasing vaccine coverage and reduce avoidable burden to  
246 health care system.

247 This study has several strengths worth highlighting. It was conducted on a large insurance  
248 claims database including both commercially and Medicare Advantage insured population.  
249 This study leveraged contemporary data from the most recent complete season during which  
250 the US COVID-19 was in an endemic setting. We were able to account for a comprehensive  
251 list of baseline variables to adjust for confounding using the stabilized IPTW, including  
252 preventive healthcare utilizations that could approximate the unmeasured health seeking  
253 behavior.

254 There are a few limitations to this study. First, given the nature of observational study, there is  
255 a possibility of residual confounding bias. Even though we controlled for a large number of  
256 baseline variables, unmeasured confounders such as occupation, lifestyle, or social interaction  
257 pattern can exist. Second, all variables, including exposure, outcomes, and baseline  
258 covariates, were derived from claims data and are susceptible to measurement errors. Such  
259 errors in this study are most likely to be non-differential between two cohorts and would bias  
260 the result towards null. Third, we imposed the continuous enrollment criteria for both baseline  
261 and follow-up period, which can introduce selection bias. Thus, the association observed in  
262 this study should be interpreted carefully and extrapolating results to other settings in terms of  
263 population, season, or age groups should be cautiously done. The current analyses were only

264 conducted over one season and would benefit from updating or replicating with more recent  
265 season data in the future. The analyses did not consider individuals who received both  
266 influenza and COVID-19 vaccines but on separate days. The association for this type of  
267 vaccination pattern with outcomes is a topic for future research.

268 **Conclusion:**

269 Results from the study suggests that receiving both COVID-19 and influenza vaccines on the  
270 same day in comparison to receipt of influenza vaccines only was associated with reduced  
271 downstream utilization of healthcare resources, especially the risk of COVID-19 related  
272 hospitalization and all-cause medical costs. Thus, interventions that could help increase vaccine  
273 coverage, especially for COVID-19 might have economic and public health benefits.



274 **References:**

- 275 1. Centers for Disease Control and Prevention. COVID Data Tracker 2024. Accessed May  
276 14, 2024, <https://covid.cdc.gov/covid-data-tracker>
- 277 2. Centers for Disease Control and Prevention. 2023-2024 U.S. Flu Season: Preliminary In-  
278 Season Burden Estimates. Accessed May 14, 2024,  
279 <https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm>
- 280 3. Centers for Disease Control and Prevention. Who Needs a Flu Vaccine. Accessed May  
281 14, 2024, <https://www.cdc.gov/flu/prevent/vaccinations.htm>
- 282 4. Centers for Disease Control and Prevention. Stay Up to Date With COVID-19 Vaccines.  
283 Accessed May 14, 2024, [https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html)  
284 [date.html](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html)
- 285 5. Centers for Disease Control and Prevention. Getting a Flu Vaccine and Other  
286 Recommended Vaccines at the Same Time. Accessed May 14, 2024,  
287 [https://www.cdc.gov/flu/prevent/coadministration.htm#:~:text=Coadministration%20of%20vacc](https://www.cdc.gov/flu/prevent/coadministration.htm#:~:text=Coadministration%20of%20vaccines%20refers%20to,This%20is%20common%20clinical%20practice.)  
288 [ines%20refers%20to,This%20is%20common%20clinical%20practice.](https://www.cdc.gov/flu/prevent/coadministration.htm#:~:text=Coadministration%20of%20vaccines%20refers%20to,This%20is%20common%20clinical%20practice.)
- 289 6. Centers for Disease Control and Prevention. COVID-19 Vaccination Coverage and  
290 Vaccine Confidence Among Adults. Updated September 23, 2021. Accessed April 30, 2024,  
291 <https://www.cdc.gov/vaccines/imz-managers/coverage/covidvaxview/interactive/adults.html>
- 292 7. Centers for Disease Control and Prevention. Flu Vaccination Coverage, United States,  
293 2022–23 Influenza Season. Accessed May 14, 2024,  
294 [https://www.cdc.gov/flu/fluview/coverage-2223estimates.htm#anchor\\_1694788906128](https://www.cdc.gov/flu/fluview/coverage-2223estimates.htm#anchor_1694788906128)

- 295 8. Maman K, Zollner Y, Greco D, Duru G, Sendyona S, Remy V. The value of childhood  
296 combination vaccines: from beliefs to evidence. *Hum Vaccin Immunother.* 2015;11(9):2132-  
297 2141. doi:10.1080/21645515.2015.1044180
- 298 9. Lin FY, Wang CH. Personality and individual attitudes toward vaccination: a nationally  
299 representative survey in the United States. *BMC Public Health.* Nov 23 2020;20(1):1759.  
300 doi:10.1186/s12889-020-09840-w
- 301 10. Mues KE, Kirk B, Patel DA, et al. Real-world comparative effectiveness of mRNA-1273  
302 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims  
303 data in the United States. *Vaccine.* 2022;40(47):6730-6739. doi:10.1016/j.vaccine.2022.09.025
- 304 11. Polinski JM, Weckstein AR, Batech M, et al. Durability of the single-dose Ad26.COV2.S  
305 vaccine in the prevention of COVID-19 infections and hospitalizations in the US before and  
306 during the delta variant surge. *JAMA Netw Open.* 2022;5(3):e222959.  
307 doi:10.1001/jamanetworkopen.2022.2959
- 308 12. Chen W, Shi J, Qian L, Azen SP. Comparison of robustness to outliers between robust  
309 poisson models and log-binomial models when estimating relative risks for common binary  
310 outcomes: a simulation study. *BMC Med Res Methodol.* 2014;14:82. doi:10.1186/1471-2288-14-  
311 82
- 312 13. McGrath LJ, Malhotra D, Miles AC, et al. Estimated Effectiveness of Coadministration  
313 of the BNT162b2 BA.4/5 COVID-19 Vaccine With Influenza Vaccine. *JAMA Netw Open.* Nov 1  
314 2023;6(11):e2342151. doi:10.1001/jamanetworkopen.2023.42151
- 315 14. Radner H, Sieghart D, Jorda A, et al. Reduced immunogenicity of BNT162b2 booster  
316 vaccination in combination with a tetravalent influenza vaccination: results of a prospective

- 317 cohort study in 838 health workers. *Clin Microbiol Infect.* 2023;29(5):635-641.  
318 doi:10.1016/j.cmi.2022.12.008
- 319 15. Lazarus R, Baos S, Cappel-Porter H, et al. Safety and immunogenicity of concomitant  
320 administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza  
321 vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.  
322 *Lancet.* Dec 18 2021;398(10318):2277-2287. doi:10.1016/S0140-6736(21)02329-1
- 323 16. Toback S, Galiza E, Cosgrove C, et al. Safety, immunogenicity, and efficacy of a  
324 COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an  
325 exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. *Lancet*  
326 *Respir Med.* 2022;10(2):167-179. doi:10.1016/S2213-2600(21)00409-4
- 327 17. Achterbergh RCA, McGovern I, Haag M. Co-administration of influenza and COVID-19  
328 vaccines: policy review and vaccination coverage trends in the European Union, UK, US, and  
329 Canada between 2019 and 2023. *Vaccines (Basel).* 2024;12(2):216.  
330 doi:10.3390/vaccines12020216
- 331 18. Moro PL, Ennulat C, Brown H, et al. Safety of simultaneous administration of bivalent  
332 mRNA COVID-19 and influenza vaccines in the Vaccine Adverse Event Reporting System  
333 (VAERS). *Drug Saf.* 2024;47(5):487-493. doi:10.1007/s40264-024-01406-8
- 334 19. Panagiotakopoulos L. Next Steps for the COVID-19 Vaccine Program. presented at:  
335 Advisory Committee on Immunization Practices; February 28, 2024 Atlanta, GA.
- 336 20. Harris DA, Chachlani P, Hayes KN, et al. COVID-19 and influenza vaccine  
337 coadministration among older U.S. adults. *Am J Prev Med.* 2024:S0749-3797(24)00067-9.  
338 doi:10.1016/j.amepre.2024.02.013

- 339 21. Kim DeLuca E, Gebremariam A, Rose A, Biggerstaff M, Meltzer MI, Prosser LA. Cost-  
340 effectiveness of routine annual influenza vaccination by age and risk status. *Vaccine*.  
341 2023;41(29):4239-4248. doi:10.1016/j.vaccine.2023.04.069
- 342 22. Fu Y, Zhao J, Han P, et al. Cost-effectiveness of COVID-19 vaccination: a systematic  
343 review. *J Evid Based Med*. 2023;16(2):152-165. doi:10.1111/jebm.12525
- 344 23. Marshall GS, Happe LE, Lunacsek OE, et al. Use of combination vaccines is associated  
345 with improved coverage rates. *Pediatr Infect Dis J*. 2007;26(6):496-500.  
346 doi:10.1097/INF.0b013e31805d7f17
- 347 24. Kurosky SK, Davis KL, Krishnarajah G. Effect of combination vaccines on completion  
348 and compliance of childhood vaccinations in the United States. *Hum Vaccin Immunother*.  
349 2017;13(11):2494-2502. doi:10.1080/21645515.2017.1362515
- 350 25. Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a  
351 Combination Vaccine Against Influenza and COVID-19. October 24, 2023,  
352 [https://news.modernatx.com/news/news-details/2023/Moderna-Announces-First-Participant-](https://news.modernatx.com/news/news-details/2023/Moderna-Announces-First-Participant-Dosed-in-Phase-3-Study-of-mRNA-1083-a-Combination-Vaccine-Against-Influenza-and-COVID-19/default.aspx)  
353 [Dosed-in-Phase-3-Study-of-mRNA-1083-a-Combination-Vaccine-Against-Influenza-and-](https://news.modernatx.com/news/news-details/2023/Moderna-Announces-First-Participant-Dosed-in-Phase-3-Study-of-mRNA-1083-a-Combination-Vaccine-Against-Influenza-and-COVID-19/default.aspx)  
354 [COVID-19/default.aspx](https://news.modernatx.com/news/news-details/2023/Moderna-Announces-First-Participant-Dosed-in-Phase-3-Study-of-mRNA-1083-a-Combination-Vaccine-Against-Influenza-and-COVID-19/default.aspx)
- 355 26. Pfizer. Pfizer and BioNTech Announce Positive Topline Data for mRNA-based  
356 Combination Vaccine Program Against Influenza and COVID-19. Accessed May 14, 2024,  
357 [https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-data-mrna)  
358 [positive-topline-data-mrna](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-data-mrna)
- 359 27. Novavax. COVID-Influenza Combination (CIC) Investigational Vaccine. Accessed May  
360 14, 2024, <https://www.novavax.com/what-we-do/vaccine-pipeline/COVID-Influenza->

361 [combination-](#)

362 [vaccine#:~:text=About%20the%20candidate,the%20influenza%20virus%2C%20as%20antigens](#)

363